natgillin/translations-raw huggingface dataset:
Luminity is used in adults to obtain a clearer scan of the chambers of the heart, especially of the left ventricle, during echocardiography (a diagnostic test where an image of the heart is obtained using ultrasound).
Zdravilo Luminity se uporablja pri odraslih za jasnejše slikanje srčnih votlin, predvsem levega prekata, med ehokardiografijo (diagnostično preiskavo, pri kateri se slika srca pridobi z ultrazvokom).
Talk to your doctor before using Luminity - if you have been told you have a heart shunt - if you have severe heart or lung diseases or if you need mechanical help to breathe - if you have an artificial valve in your heart - if you have an acute severe inflammation/sepsis - if you have known hyperactive coagulation system (blood clotting issues) or recurrent thromboembolism (blood clots) - if you have a liver disease - if you have a kidney disease
- če so vam povedali, da imate srčni spoj (šant), - če imate hudo bolezen srca ali pljuč ali če za dihanje potrebujete mehanično podporo, - če imate umetno srčno zaklopko, - če imate hujše akutno vnetje/sepso, - če je znano, da imate hiperaktivni koagulacijski sistem (težave s strjevanjem krvi) ali ponavljajočo se trombembolijo (krvne strdke),
- The dispersion should be withdrawn from the vial using a syringe with a 18 to 20 gauge sterile needle or attached to a sterile non-siliconised mini-spike.
- Disperzijo morate izvleči iz viale z brizgo, ki ima nameščeno sterilno iglo številka 18 do 20 ali sterilno nesilikonizirano mini-konico.
Rats treated with Luminity for 1 month exhibited dose-related, reversible perivascular and peribronchiolar eosinophil infiltration, alveolar macrophage accumulation and increased goblet cell size and number in the lungs.
Pri podganah, ki so 1 mesec dobivale Zdravilo Luminity, so ugotovili z odmerkom povezano, reverzibilno perivaskularno in peribronhiolarno infiltracijo z eozinofilci, alveolarno kopičenje makrofagov ter povečanje velikosti in števila čašastih celic v pljučih.
Luminity is given to you before or during your ultrasound examination by healthcare professionals such as doctors who are experienced in this type of examination.
Zdravilo Luminity boste dobili pred preiskavo z ultrazvokom ali med njo; dal vam ga bo zdravstveni delavec, npr. zdravnik, ki ima izkušnje s takšnimi preiskavami.
• increased sweating,
• srbenje, • močnejše znojenje,
The ultrasonic properties of the product are very different from those of soft tissue and will generate strong echoes.
Luminity se zelo razlikujejo od lastnosti mehkih tkiv in povzročijo močan odboj.
The product can be re-activated up to 48 hours after initial activation and used up to 12 hours after the second activation.
Zdravilo lahko reaktivirate do 48 ur po prvem aktiviranju in ga uporabite do 12 ur po drugem aktiviranju.
How to use Luminity
Kako uporabljati zdravilo Luminity
Intravenous infusion using non-linear contrast imaging technique (rest and stress) or fundamental imaging technique at rest:
Intravensko infundiranje z uporabo nelinearnega načina kontrastnega slikanja (mirovanje in obremenitev) ali osnovnih načinov slikanja v mirovanju:
This product must only be administered intravenously.
To zdravilo se sme dajati samo intravensko.
Luminity is for diagnostic use only.
Zdravilo Luminity je samo za diagnostične namene.
Luminity should only be administered to such patients after careful risk/benefit assessment.
Pri teh bolnikih se sme zdravilo Luminity uporabljati le po skrbnem ovrednotenju razmerja med koristjo in tveganjem.
• loss of consiousness,
• izguba zavesti,
Luminity is an ultrasound contrast agent that contains microspheres (tiny bubbles) of perflutren gas as the active substance.
Zdravilo Luminity je kontrastno sredstvo za ultrazvočne preiskave, ki vsebuje mikrosfere (drobne mehurčke) s plinom perflutren kot učinkovino.
Fundamental and non-linear imaging techniques (second harmonic, multipulse phase and/or amplitude modulation) using both continuous and triggered acquisition were utilised in clinical studies with Luminity.
V kliničnih študijah z zdravilom Luminity so bile uporabljene osnovne in nelinearne preiskovalne metode (“second harmonic”, “multipulse phase” in/ali “amplitude modulation”) pri čemer je bil uporabljen tako kontinuiran kot pulzirajoč signal.
The safety of Luminity in patients with right-to-left, bi-directional or transient right-to-left cardiac shunts has not been studied.
Varnost zdravila Luminity ni raziskana pri bolnikih z desno-levimi, dvosmernimi ali prehodnimi desno-levimi srčnimi spoji (šanti).
• pain at the site of injection.
• občutek vročine in • bolečina na mestu injiciranja.
Like all parenteral products, the vials must be inspected visually for particulates and vial integrity.
Kot velja za vsa parenteralna zdravila, morate viale pred uporabo pregledati in preveriti glede delcev in nepoškodovanosti viale.
All lipids are metabolised to free fatty acids.
Vsi lipidi se presnovijo v proste maščobne kisline.
Luminity is a gas and solvent for dispersion for injection or infusion.
Zdravilo Luminity je plin in vehikel za disperzijo za injiciranje ali infundiranje.
What Luminity looks like and contents of the pack
Izgled zdravila Luminity in vsebina pakiranja
During contrast-enhanced echocardiography, serious cardiopulmonary reactions, including fatalities, have occurred during or within 30 minutes of Luminity administration in patients including those with severe cardiac and pulmonary diseases (see section 4.8).
Bolniki z nestabilnim kardiopulmonalnim stanjem Med izvajanjem kontrastne ehokardiografije ali v 30 minutah po uporabi zdravila Luminity so pri bolnikih, vključno z bolniki s hudo boleznijo srca in pljuč, poročali o pojavu hudih kardiopulmonalnih reakcij, tudi s smrtnimi izidi (glejte poglavje 4.8).
The dispersion should be given to you within 12 hours of activation (shaking).
Disperzijo morate dobiti v 12 urah po aktiviranju (stresanju).
Not known: Abnormal vision
Očesne bolezni neznana: nenormalen vid
Luminity should be used within 12 hours following activation.
Zdravilo Luminity morate uporabiti v 12 urah po aktiviranju.
If you have had an allergic reaction in the past with Luminity or any other ultrasound contrast agent tell your doctor.
Če ste že kdaj prejeli zdravilo Luminity ali katero koli drugo kontrastno sredstvo, ki ga uporabljamo pri ultrazvočnih preiskavah, in se je pri tem pojavila alergijska reakcija, o tem obvestite svojega zdravnika.
Luminity contains sodium.
Zdravilo Luminity vsebuje natrij.
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodiumfree' .
Zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na odmerek, kar dejansko pomeni, da je “brez natrija”.
- if you are allergic to perflutren or any of the other ingredients of Luminity.
- če ste alergični na perflutren ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Gas and solvent for dispersion for injection/infusion 1 x 1.5 ml single-dose vial 4 x 1.5 ml single-dose vials
plin in vehikel za disperzijo za injiciranje/infundiranje 1 x 1,5-ml viala z enim odmerkom
As Luminity has no pharmacologic effect, and on the basis of its pharmacokinetic and pharmacodynamic profiles, no or negligible influence is expected with the use of this product on the ability to drive or use machines.
Glede na farmakokinetične in farmakodinamične lastnosti ni pričakovati vpliva na sposobnost vožnje in upravljanja s stroji oz. je pričakovani vpliv zanemarljiv.
Tell your doctor if you are pregnant or breast-feeding and ask your doctor or pharmacist for advice before you are given Luminity.
Preden dobite zdravilo Luminity, morate zdravniku ali farmacevtu povedati, če ste noseči ali če dojite,
The product consists of lipid encapsulated perflutren microspheres.
Zdravilo sestavljajo mikrosfere perflutrena, inkapsulirane z lipidom.
The product should be used within 12 hours of activation.
Zdravilo je treba uporabiti v 12 urah po aktiviranju.
• rash, redness of the skin,
• izpuščaj, pordelost kože,
Rare side effects (may affect up to 1 in 1000 people)
Redki neželeni učinki (pojavijo se lahko pri največ 1 od 1.000 bolnikov)
Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).
Študije na živalih ne kažejo na neposredne ali posredne škodljive vplive na nosečnost, razvoj zarodka/plodu,
Before administering Luminity, the medicinal product must be activated by using a mechanical shaking device, the Vialmix, see section 6.6.
Pred uporabo je treba zdravilo Luminity aktivirati z uporabo mehanskega stresalnika Vialmix, glejte poglavje 6.6.
Patients should be closely monitored and administration should be under the direction of a physician experienced in the management of hypersensitivity reactions including severe allergic reactions, which might require resuscitation.
Zdravilo se sme uporabljati le pod neposrednim nadzorom zdravnika, ki ima izkušnje z ukrepanjem v primeru pojava preobčutljivostnih reakcij, vključno s hudimi alergijskimi reakcijami,
The approximate amount of perflutren gas in each ml is 150 microlitres (μl).
Približna količina plina perflutrena je 150 mikrolitrov (μl) na mililiter.
Preclinical data reveal no special hazard for humans based on conventional studies of genotoxicity, fertility, embryo/foetal development, parturition or post-natal development, and local tolerance.
Predklinični podatki na osnovi običajnih študij genotoksičnosti, plodnosti, embrio-fetalnega razvoja, porajanja ali postnatalnega razvoja in lokalnega prenašanja ne kažejo posebnega tveganja za človeka.
The total dose of perflutren should not exceed 1.6 ml.
Celotni odmerek perflutrena ne sme preseči
The systemic clearance of perflutren was similar in healthy and COPD subjects.
Sistemski očistek perflutrena je bil pri zdravih osebah in bolnikih s KOPB podoben.
Caution must be exercised when considering the administration of Luminity to these patients.
Zato se morate za uporabo zdravila Luminity pri takšnih bolnikih odločiti previdno.
Gas and solvent for dispersion for injection/infusion Colourless, uniformly clear to translucent liquid.
plin in vehikel za disperzijo za injiciranje/infundiranje brezbarvna, enakomerno bistra do prosojna tekočina
• increased blood pressure,
• omedlevica, • zvišan krvni tlak,
• altered heart rate, palpitations (you feel your heart beats harder or in an irregular way),
• otrplost, mravljinčenje ali pekoč občutek, • spremenjen srčni utrip, palpitacije (občutek močnejšega ali nerednega bitja srca),
Overdose is not likely to happen since the medicine is administered by a doctor.
Verjetnost prevelikega odmerjanja tega zdravila je majhna, saj vam ga bo injiciral zdravnik.
Not known: Cardiac arrest, ventricular arrhythmias (ventricular fibrillation, ventricular tachycardia, premature ventricular contactions), asystole, atrial fibrillation, cardiac ischaemia, supraventricular tachycardia, supraventricular arrhythmia
Srčne bolezni redki: bradikardija, tahikardija, palpitacije neznana: srčni zastoj, ventrikularne aritmije (ventrikularna fibrilacija, ventrikularna tahikardija, prezgodnje krčenje prekatov), asistolija, atrijska fibrilacija, srčna ishemija,
In most subjects after 4-5 minutes, perflutren was undetectable in blood and expired air. Perflutren concentrations in blood were shown to decline in a mono-exponential fashion with a mean half-life of 1.3 minutes in healthy subjects and 1.9 minutes in COPD subjects.
Ugotovljeno je, da koncentracija perflutrena v krvi upada monoeksponentno, in sicer s povprečnim razpolovnim časom, ki je pri zdravih preiskovancih 1,3 minute in pri preiskovancih s KOPB 1,9 minute.
The pharmacokinetic properties of Luminity were evaluated in normal healthy subjects and subjects with chronic obstructive pulmonary disease (COPD) following intravenous administration of a 50 µl/kg dose of the product.
Farmakokinetične lastnosti zdravila Luminity so ocenili pri normalnih zdravih preiskovancih in pri preiskovancih s kronično obstruktivno pljučno boleznijo (KOPB) po intravenski aplikaciji odmerka
Extreme caution should be used when considering the administration of Luminity to patients with unstable cardiopulmonary status, for example: unstable angina, acute myocardial infarction, severe ventricular arrhythmias, severe heart failure (NYHA IV) or respiratory failure.
Pri bolnikih z nestabilnim kardiopulmonalnim stanjem je treba zdravilo Luminity uporabljati izjemno previdno, npr. pri bolnikih z nestabilno angino pektoris, akutnim miokardnim infarktom, s hudo ventrikularno aritmijo, hudim srčnim popuščanjem
The reported adverse reactions following the use of Luminity in pivotal and supportive trials (total of 2,526 patients) occur within minutes after administration and usually resolve without therapeutic intervention within 15 minutes.
bolnikih) so se pojavili v nekaj minutah po aplikaciji in so ponavadi v 15 minutah minili brez terapevtskega ukrepanja.
- The vial should be vented with a sterile syringe needle or a sterile non-siliconised mini-spike before withdrawing the dispersion.
- Preden izvlečete disperzijo, zabodite v vialo sterilno injekcijsko iglo ali sterilno, nesilikonizirano mini-konico, da bo viala odzračena.
• breathing problems, cough, dry throat, difficulty in swallowing,
• težave z dihanjem, kašelj, suho žrelo, težave s požiranjem,
The approximate amount of perflutren gas in each ml of Luminity is 150 microlitres.
Približna količina plina perflutrena je 150 mikrolitrov na mililiter zdravila Luminity.
• fatigue,
• utrujenost,
After activation: Do not store above 30°C.
Po aktiviranju: Shranjujte pri temperaturi do 30 °C.
After activation (shaking), the product appears as a milky white liquid.
Po aktiviranju (stresanju) ima videz mlečno bele disperzije.
Uncommon: Hypotension Rare: Syncope, hypertension, peripheral coldness
Žilne bolezni pogosti: zardevanje občasni: hipotenzija redki: sinkopa, hipertenzija, hladne okončine
• abdominal pain, diarrhoea, nausea (feeling sick), vomiting,
• bolečina v trebuhu, driska, navzea (siljenje na bruhanje), bruhanje,
After activation (shaking), do not store above 30°C.
Po aktiviranju (stresanju) shranjujte pri temperaturi do 30 °C.
• difficulty in breathing, throat irritation,
• težko dihanje, draženje žrela,
Elderly Pharmacokinetics has not been specifically studied in the elderly.
Farmakokinetike pri starostnikih niso posebej preučevali.
Each ml contains a maximum of 6.4 x 109 perflutren-containing lipid bubbles, with an average diameter range of 1.1-2.5 micrometres.
En mililiter vsebuje največ 6,4 x 109 lipidnih mehurčkov, ki vsebujejo perflutren; povprečni razpon njihovega premera je od 1,1 do 2,5 mikrometra.
• joint pain, pain on the side(s), neck pain, muscle cramp, fever, muscle stiffness
• bolečina v sklepih, bolečina ob strani/ob straneh, bolečine v vratu, mišični krč, zvišana telesna temperatura, mišična togost in
Administration and mechanical activation procedure Luminity should not be administered by methods not specified in section 4.2 (e.g. intra-arterial injection).
Zdravila Luminity se ne sme aplicirati na noben drug način (npr. intraarterijsko injiciranje).
• back pain, chest pain,
• bolečina v hrbtu, bolečina v prsih,
Luminity is an ultrasound contrast-enhancing agent for use in adult patients in whom non-contrast echocardiography was suboptimal (suboptimal is considered to indicate that at least two of six segments in the 4- or 2-chamber view of the ventricular border were not evaluable) and who have suspected or established coronary artery disease, to provide opacification of cardiac chambers and improvement of left ventricular endocardial border delineation at both rest and stress.
(pri projekciji “štirih” ali “dveh votlin” vsaj dveh od šestih segmentov prekatne stene ni bilo možno ovrednotiti), da bi tako dosegli opacifikacijo srčnih votlin in boljšo zamejitev endokardialne meje levega prekata tako v mirovanju kot med obremenitvijo.
1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) 1,2-dipalmitoyl-sn-glycero-3-phosphatidic acid, monosodium salt (DPPA) N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3phosphatidylethanolamine, monosodium salt (MPEG5000 DPPE) Sodium dihydrogen phosphate monohydrate Disodium hydrogen phosphate heptahydrate Sodium chloride
1,2-dipalmitoil-sn-glicero-3-fosfatidilholin (DPPC) 1,2-dipalmitoil-sn-glicero-3-fosfatidilna kislina, mononatrijeva sol (DPPA) N-(metoksipolietilenglikol 5000 karbamoil)-1,2-dipalmitoil-sn-glicero-3fosfatidiletanolamin, mononatrijeva sol (MPEG5000 DPPE) natrijev dihidrogenfosfat monohidrat natrijev hidrogenfosfat heptahidrat natrijev klorid propilenglikol glicerol voda za injekcije
Do not use Luminity after the expiry date which is stated on the carton and label after EXP. Before activation (shaking), store in a refrigerator (2°C - 8°C).
Pred aktiviranjem (stresanjem) shranjujte v hladilniku (2 °C - 8 °C).
Single doses of up to 100 microlitres dispersion/kg and multiple doses up to 150 microlitres dispersion/kg were tolerated well in Phase I clinical trials.
V kliničnih preskušanjih I. faze so bolniki dobro prenesli posamične odmerke do 100 mikrolitrov disperzije/kg in večkratne odmerke do 150 mikrolitrov disperzije/kg.
• itching,
• omotica,
Total lung clearance (CLlung) of perflutren was shown to be no different in healthy subjects compared to COPD subjects.
Ugotovljeno je, da se celotni pljučni očistek (CLpljučni) perflutrena med zdravimi preiskovanci in preiskovanci s KOPB ne razlikuje.
Serious immediate hypersensitivity reactions (eg: anaphylaxis, anaphylactic shock and anaphylactoid reactions, hypotension and angioedema) have been reported following the administration of Luminity.
Po uporabi zdravila Luminity so poročali o pojavu resnih takojšnjih preobčutljivostnih reakcij (npr. anafilaksija, anafilaktični šok in anafilaktoidne reakcije, hipotenzija ter angioedem).
Each ml contains maximum 6.4 x 109 perflutren-containing lipid microspheres with a mean diameter range of 1.1-2.5 μm (approximately 150 microlitres perflutren gas per ml).
NAVEDBA ENE ALI VEČ UČINKOVIN En mililiter vsebuje največ 6,4 x 109 perflutren vsebujočih lipidnih mikrosfer s povprečnim razponom premera od 1,1 do 2,5 μm (približno 150 mikrolitrov plina perflutrena na mililiter).
Luminity is then given into a vein either as a ‘bolus' injection (given all at once) or as an infusion (drip solution) after being diluted with sodium chloride 9 mg/ml (0.9%) or glucose 50 mg/ml (5%) solution for injection.
Zdravilo Luminity se daje v veno kot injiciranje »bolusa« (celotni odmerek se vbrizga naenkrat) ali kot infundiranje (kapalna raztopina) po redčenju z raztopino za injiciranje z 9 mg/ml natrijevega klorida (0,9 %) ali 50 mg/ml glukoze (5 %).
Pharmacotherapeutic group: ultrasound contrast media, microspheres of phospholipids, ATC Code: V08DA04
5.1 Farmakodinamične lastnosti Farmakoterapevtska skupina: ultrazvočna kontrastna sredstva, mikrosfere fosfolipidov,
Patients with adult respiratory distress syndrome, endocarditis, prosthetic heart valves, systemic inflammation, sepsis, hyperactive coagulation and/or recurrent thromboembolism Luminity should be used only after careful consideration and such use should be monitored closely during administration in patients with adult respiratory distress syndrome, endocarditis, a heart with prosthetic valves, acute states of systemic inflammation or sepsis, known states of hyperactive coagulation and/or recurrent thromboembolism.
Zdravilo Luminity se sme uporabljati le po skrbnem premisleku pri bolnikih s sindromom dihalne stiske pri odraslem, z endokarditisom, umetnimi srčnimi zaklopkami, akutnimi stanji sistemskega vnetja ali sepso, znanimi stanji hiperaktivnosti sistema koagulacije in/ali ponavljajočo se trombembolijo.
Excipients: 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC), 1,2-dipalmitoyl-sn-glycero-3-phosphatidic acid, monosodium salt (DPPA), N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine, monosodium salt (MPEG5000 DPPE), sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate heptahydrate, sodium chloride, propylene glycol, glycerol, water for injections
Pomožne snovi: 1,2-dipalmitoil-sn-glicero-3-fosfatidilholin (DPPC), 1,2-dipalmitoil-sn-glicero-3fosfatidilna kislina, mononatrijeva sol (DPPA), N-(metoksipolietilenglikol 5000 karbamoil)-1,2dipalmitoil-sn-glicero-3-fosfatidiletanolamin, mononatrijeva sol (MPEG5000 DPPE), natrijev dihidrogenfosfat monohidrat, natrijev hidrogenfosfat heptahidrat, natrijev klorid, propilenglikol, glicerol, voda za injekcije
Before administering the product, it must be activated by using the Vialmix, a mechanical shaking device.
Pred apliciranjem je treba zdravilo Luminity aktivirati z Vialmixom, mehanično napravo za stresanje.
- The other ingredients are 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC), 1,2dipalmitoyl-sn-glycero-3-phosphatidic acid, monosodium salt (DPPA), N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine, monosodium salt (MPEG5000 DPPE), sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate heptahydrate, sodium chloride, propylene glycol, glycerol and water for injections.
Pomožne snovi so 1,2-dipalmitoil-sn-glicero-3-fosfatidilholin (DPPC), 1,2-dipalmitoil-sn-glicero-3fosfatidilna kislina, mononatrijeva sol (DPPA), N-(metoksipolietilenglikol 5000 karbamoil)-1,2dipalmitoil-sn-glicero-3-fosfatidiletanolamin, mononatrijeva sol (MPEG5000 DPPE), natrijev dihidrogenfosfat monohidrat, natrijev hidrogenfosfat heptahidrat, natrijev klorid, propilenglikol, glicerol in voda za injekcije.
The recommended dose via an intravenous infusion is 1.3 ml dispersion added to 50 ml of sodium chloride 9 mg/ml (0.9%) or glucose 50 mg/ml (5%) solution for injection.
Priporočeni odmerek intravenske infuzije je 1,3 ml disperzije, dodane 50 ml 9 mg/ml (0,9 %) raztopine natrijevega klorida za injiciranje ali 50 mg/ml (5 %) raztopine glukoze za injiciranje.
Luminity should only be administered by trained physicians with technical expertise in performing and interpreting contrast echocardiograms, and appropriate resuscitation equipment should be available in case of cardiopulmonary or hypersensitivity reactions (see section 4.4).
Zaradi možnega pojava kardiopulmonalnih ali preobčutljivostnih reakcij je pri uporabi zdravila Luminity treba imeti na voljo ustrezno opremo za oživljanje (glejte poglavje 4.4).
• peripheral coldness,
• hladne okončine,
How to store Luminity
Shranjevanje zdravila Luminity
Abnormal respiration, heart rate changes and decreased activity were observed soon after intravenous injection of Luminity at doses ≥ 0.3 ml/kg in single and repeat-dose toxicity studies in rats and monkeys.
V študijah toksičnosti posamičnih in ponavljajočih se odmerkov pri podganah in opicah so po intravenskem injiciranju zdravila Luminity v odmerkih ≥ 0,3 ml/kg opažali nenormalno dihanje,
Therefore, caution should be exercised when Luminity is administered to breast-feeding women.
V primeru uporabe zdravila Luminity pri doječih ženskah je zato potrebna previdnost.
Microspheres in the 1 to < 10 µm diameter size range contribute to the contrast effect by generating strongly enhanced echoes.
< 10 µm močno ojačijo odboj in tako pripomorejo h kontrastnemu učinku.
Rare: Arthralgia, flank pain, neck pain, muscle cramp Not known: Muscle spasm, musculoskeletal pain, musculoskeletal discomfort, myalgia, hypertonia
Bolezni mišično-skeletnega sistema in vezivnega tkiva občasni: bolečina v hrbtu redki: artralgija, bolečina v bokih, bolečina v vratu, mišični krč neznana pogostnost: mišični spazem, mišičnoskeletna bolečina, mišičnoskeletno neudobje, mialgija, hipertonija
As Luminity consists of microspheres that are stable and small enough for transpulmonary passage, enhanced echo signals in the left heart and systemic circulation are obtained.
Zdravilo Luminity sestavljajo mikrosfere, ki so stabilne in dovolj majhne, da preidejo skozi pljuča.
Before activation (shaking) the contents of the vial, Luminity appears as a colourless, uniformly clear to translucent liquid.
(stresanjem) vsebine viale je zdravilo Luminity brezbarvna, enakomerno bistra do prosojna tekočina.